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Background: Many current therapies for metastatic castration-resistant prostate cancer (mCRPC) are aimed at AR
signaling; however, resistance to these therapies is inevitable. To personalize CRPC therapy in an individual with
clinical progression despite maximal AR signaling blockade, it is important to characterize the status of AR activity
within their cancer. Biopsies of bone metastases are invasive and frequently fail to yield sufficient tissue for further
study. Evaluation of circulating tumor cells (CTCs) offers an alternative, minimally invasive mechanism to characterize
and study late-stage disease. The goal of this study was to evaluate the utility of CTC interrogation with respect to
the AR as a potential novel therapeutic biomarker in patients with mCRPC.
Methods: Fifteen mL of whole blood was collected from patients with progressive, metastatic mCRPC, the
mononuclear cell portion was isolated, and fluorescence-activated cell sorting (FACS) was used to isolate and
evaluate CTCs. A novel protocol was optimized to use ImageStreamX to quantitatively analyze AR expression and
subcellular localization within CTCs. Co-expression of AR and the proliferation marker Ki67 was also determined
using ImageStreamX.
Results: We found inter-patient and intra-patient heterogeneity in expression and localization of AR. Increased AR
expression and nuclear localization are associated with elevated co-expression of Ki-67, consistent with the
continued role for AR in castration-resistant disease. Despite intra-patient heterogeneity, CTCs from patients with prior
exposure to abiraterone had increased AR expression compared to CTCs from patients who were abiraterone-naïve.
Conclusions: As our toolbox for targeting AR function expands, our ability to evaluate AR expression and function
within tumor samples from patients with late-stage disease will likely be a critical component of the personalized
management of advanced prostate cancer. AR expression and nuclear localization varies within patients and between
patients; however it remains associated with markers of proliferation. This supports a molecularly diverse AR-centric
pathobiology imparting castration-resistance.
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Metastatic prostate cancer is the 2nd-leading cause of can-
cer mortality among American men [1] and is associated
with significant morbidity in addition to loss of life.
Androgen deprivation and other methods to disrupt an-
drogen receptor (AR) signaling were the first targeted can-
cer therapy and have been the mainstay of prostate cancer
therapy for more than seven decades [2]. Two recently
approved therapies for advanced prostate cancer directly
target the androgen receptor signaling pathway: abirater-
one by preventing androgen synthesis, and enzalutamide
by blocking interaction of the receptor with its ligands.
There is even evidence that docetaxel, the first approved
systemic therapy with a demonstrated survival benefit, acts
by disrupting AR function [3].
Though most men with prostate cancer initially respond
to these AR-targeted therapies, resistance is inevitable. As
with other targeted therapies, alteration or modification of
the target is a likely resistance mechanism and a number
of such mechanisms have already been described including
upregulation of AR expression, as well as mutation and de-
letion of the AR ligand binding domain [4-9]. Neverthe-
less, translational studies, including assessment of clinical
relevance of various AR alterations, have been hampered
by a lack of access to tissue. Prostate cancer typically me-
tastasizes to bone, and biopsy of these lesions is invasive,
painful, and low yield [10]. A few programs have instituted
warm autopsy programs, collecting samples of metastatic
disease shortly after willing patients die from their disease
[11]. These programs are rare, however, and offer only a
final snapshot of the biology of resistant disease.
Circulating tumor cells (CTCs) are emerging as a source
of therapy-resistant prostate cancer material, a so-called
“liquid biopsy” that could serve as a therapeutic biomarker
[12,13]. CTCs can be obtained through relatively non-
invasive means, opening the door to serial assessments
of the disease state and examine tumor cell response to
therapy. In 2008 the FDA approved the use of the
CELLSEARCH system (Janssen Diagnostics) to collect and
enumerate CTCs in patients with prostate cancer [14].
With this system, there is a clear relationship between the
number of CTC’s and disease prognosis. Additional
methods for CTC isolation have been developed, including
microfluidic techniques [15], RT-PCR detection [16], fluor-
escence in situ hybridization (FISH) [17], and enrichment
based approaches using other magnetic devices [18-21],
lipid content [22], size [23,24], or charge. Many of these
technologies are confounded by white blood cell (WBC)
contamination, are often dependent on fixed cells, have
focused on CTC enumeration, and have not necessarily
been conducive to molecular interrogation of isolated
cells.
We sought to develop and utilize techniques that allow
flexibility in translational application. The eventual goalof our research is to provide support for CTC protein
interrogation as a predictive therapeutic biomarker for
the personalization of mCRPC care. As AR is the pivotal
molecular driver of prostate cancer evolution and pro-
gression and is the foremost therapeutic target for
mCRPC, our current study focused on AR interrogation.
To that end we used fluorescence activated cell sorting
(FACS)-based methods allowing for protein analysis and
collection of live cells. We focused our approach using
ImageStreamX, which combines microscopy techniques
with flow cytometry. ImageStreamX captures each cellu-
lar event in a digital photograph and calculates multiple
parameters, including fluorescence intensity and loca-
tion, within each captured image [25-27]. This flexibility
and specificity allowed an integrated evaluation of AR
within CTCs in patients with metastatic castration-
resistant prostate cancer (mCRPC).
Methods
Patients
All patients were treated at the University of Chicago for
mCRPC and provided informed consent per an Insti-
tutional Review Board-approved prospective clinical
protocol. All patients were progressing on their current
therapy by PSA or radiologic criteria. Blood (15 mL) was
collected and processed within 2 hours, including isola-
tion of mononuclear cell fraction (buffy coat). Two co-
horts were evaluated: our initial cohort of FACS-sorted
CTCs evaluated by immunofluorescent microscopy, and
a second cohort of 20 patients with CTCs evaluated by
ImageStreamX.
Isolation of CTCs by FACS
Patient blood was drawn into blood collection tubes
(BD: 362753). Isolated mononuclear cells were stained
with either an Alexa-488 conjugated EpCAM antibody
(Biolegend, 1:100) or a PE-conjugated EpCAM antibody
(Biolegend, 1:100) and a QDot800 conjugated CD45
antibody (Invitrogen, 1:100). CTCs were isolated using a
MoFlo XDP flow-sorting machine to sort for EpCAM
positive/CD45 negative cells.
Protein expression by immunofluoresence (IF)
Isolated CTCs that were utilized for protein expression
analysis via immunofluoresence (IF) were sorted into 8-
chambered slides (LAB-TEK: 154941). CTC cells were
stained with combinations of the following primary anti-
bodies overnight and secondary antibodies: Androgen Re-
ceptor (Santa Cruz, N-20 antibody, 1:100) or an Alexa-647
conjugated AR antibody (Cell Signaling, AR-XP, 1:100),
PSA (Santa Cruz 7638 1:50), PE conjugated pan-cytokeratin
(Santa Cruz 8018, 1:50), DyLight 680 anti-rabbit secondary
(KPL, 1:100), Dylight 594 anti-goat (KPL, 1:100). DAPI
containing mounting media was used to coverslip slides
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the Leica SP2 laser scanning confocal microscope and im-
ages were analyzed using ImageJ software.
Targeted DNA sequencing
To extract and amplify DNA, sorted cells were collected
into PCR tubes containing 3 μl PBS and DNA extracted
using REPLI-g (Qiagen) following the manufacturer’s in-
structions for amplification from single cells. To sequence
a portion of the AR gene, primers were used to amplify
exons 7 and 8, and the forward primer used for capillary
sequencing. (AR intron7 F GAGGCCACCTCCTTGT
CAACCCTG and AR 3UTR R2 GGCACTGCAGAG
GAGTAGTGCAGA).
ImageStreamX analysis
Analysis of CTCs from patients with mCRPC
Buffy coat obtained from patients with mCRPC for Ima-
geStreamX analysis was centrifuged at 450 G for 10 minutes
and washed with PBS. Cells were blocked using FcR Block-
ing Reagent (Miltenyi Biotec, 1:10) for 10 minutes. One μl
of Biotin anti-human CD45 (Biolegend, 1:100) per 5 × 106
cells was added, incubated for 20 minutes, washed with
PBS, and centrifuged for 10 minutes at 450 G. This was re-
peated twice. Anti-biotin microbeads (Miltenyi, 1:4) were
added to cells at a 1:4 dilution per 107 cells for 15 min,
washed with PBS, and centrifuged at 450 G. Cells were re-
suspended in 500 μl PBS and CD45 depleted using Auto-
MACS Pro (Miltenyi) per the manufacturer’s instructions.
Following depletion, cells were centrifuged for 10 minutes
at 450 G, washed and fixed for 15 minutes with 3.2% Ultra
Pure EM Grade Formaldehyde (Polysciences, Inc., 1:6),
and stored at 4C for up to three months (average storage
time was 4 weeks). Staining was performed using EpCAM
(Biolegend;1:40), and CD45 (Life Technologies; 1:27)
antibodies in the dark for 30 minutes. For intracellular
staining, cells were then washed with PBS. Fix/perm buffer
from FoxP3 Buffer Set (eBioscience, 1:4) was added to cells
for 30 minutes then washed off with PBS. Next, cells were
washed with Perm Buffer from FoxP3 Buffer Set
(eBioscience, 1:10) and centrifuged at 450 G for 5 minutes.
Cells were stained intracellularly with AR (Cell Signaling,
1:11), and Ki-67 (Biolegend, 1:11) in the dark for one hour.
Cells were washed with Perm Buffer and then PBS. Finally,
cells were stained with FxCycle Violet (Invitrogen, 1:1000)
and acquired on ImageStreamX (Amnis). Single stain con-
trol with gaiting strategy for each antibody is shown in
Additional file 1: Figure S1. Gating strategies and multi-
marker compensation were maintained. Analysis was con-
ducted using IDEAS software (Amnis).
Comparison of staining fixed versus unfixed cells
One million LAPC-4 cells were fixed for 15 minutes with
3.2% Ultra Pure EM Grade Formaldehyde (Polysciences,Inc.). Fixed cells and an equal number of unfixed LAPC-4
cells were washed with 1× PBS and centrifuged for 5 mi-
nutes at 450 G. Following centrifugation, cells were stained
with EpCAM (Biolegend, 1:40) for 30 minutes at 4C then
washed with PBS. Both fixed and unfixed cells were ana-
lyzed via flow cytometry. FACSDiVa Software was used for
data acquisition and FlowJo software was used for analysis.Determination of Nuclear versus Cytoplasmic AR
localization
LAPC-4 cells were cultured in serum starved media. On
day 1, either 1 μM R1881 or 10 μM of enzalutamide was
added to the cells. On day 2 cells were intracellularly
stained for AR as described above.Single stain compensation controls
VCAP or CWR22RV1 cells were fixed for 15 minutes
with 3.2% Ultra Pure EM Grade Formaldehyde (Poly-
sciences, Inc.). Cells were washed with PBS, centrifuged
for 5 minutes, and stained for EpCAM (Biolegend, 1:40),
CD45 (Life Technologies, 1:27), AR (Cell Signaling, XP
conjugated antibody, 1:11), Ki-67 (Biolegend, 1:11) and
FxCycle Violet (Invitrogen, 1:1000). Cells were acquired
using ImageStreamX (Amnis; Seattle, WA) and analyzed
using IDEAS software (Amnis; Seattle, WA).Evaluation of cell proliferation
A mitomycin dose response curve was performed on
CWR22RV1 between 1 ug/ml to 8 ug/ml, and cells were
incubated for 4 hours. The media was replaced, and the
cells were incubated overnight. Cells were stained for
Ki-67 and analyzed by ImageStreamX.Statistical analyses
For our initial feasibility cohort, a detection rate of 35%
was postulated as the minimum threshold of feasibility
given the reported detection rate for CTCs between 50
and 70%. Thus, a minimum of six of the first fifteen ana-
lyzed patients needed to have isolated and visualized
CTCs to satisfy our feasibility threshold and allow the
study to continue.
A student’s t test was used to analyze the difference in
Ki-67 expression following exposure to Mitomycin. A
Wilcoxon signed-rank test was used to analyze the asso-
ciation between Ki-67 and AR expression, and between
Ki-67 and similarity index. A Wilcoxon rank sum test
was used to analyze the association between AR expres-
sion and prior exposure to abiraterone, and between
similarity index and prior exposure to abiraterone. A
mixed model with a random patient effect was used to
analyze the difference in area between EpCAM+ and
EpCAM- cells.
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Feasibility of CTC isolation and interrogation
The initial step in determining feasibility of androgen re-
ceptor (AR) characterization in CTCs involved spike-in
experiments in which cells from the well-established
prostate cancer cell line LAPC-4 were introduced into
whole blood from healthy donors. After immunostaining
for epithelial (EpCAM) and white blood cell (WBC)
markers (CD45), EpCAM+/CD45- events were isolated
using FACS and sorted onto slide chambers for im-
munofluorescence (IF) (Figure 1A). Enucleated cell deb-
ris was among the events sorted by FACS, but IF
confirmed the identity of DAPI+/EpCAM+/CD45- can-
cer cells (Figure 1A). These cells were also found to ex-
press pan-cytokeratin, further supporting their identity
as prostate cancer cells (Figure 1A). Of note, with these
methods, using prostate cancer cells spiked into volun-
teer blood, there was large loss of cancer cells through-
out the process (up to 90%, data not shown). As the
focus of our study was on molecular characterization,
not enumeration, we proceeded with these methods des-
pite large loss and potential lack of enumeration sensitiv-
ity. To determine the feasibility for these methodologies in
interrogating AR protein expression, similar spike-in
experiments were performed with the LAPC-4 human
prostate cancer cell line, which is known to overexpress
AR [28]. As expected, AR was visualized and found to
be nuclear in the AR-positive cell line LAPC-4, butFigure 1 Isolation and evaluation of cultured prostate cancer cells. A.
donors were sorted onto slide chambers for immunofluorescence (IF) using
EpCAM. They were evaluated for presence of a nucleus with DAPI and exp
AR-negative DU145 cells spiked into whole blood from healthy donors wer
localization. C. Ten C4-2 cells spiked into whole blood from a healthy dono
extracted DNA underwent whole genome amplification. A portion of the A
sequencing, and a known T→C mutation was identified.absent in the AR-negative prostate cancer cell line
DU145 (Figure 1B).
To further confirm the specificity of FACS-sorted
events, C4-2 cells harboring a known mutation in AR were
spiked into whole blood from healthy donors. As few as
ten EpCAM+/CD45- C4-2 cells were sorted into PBS, and
DNA was amplified using multiple displacement amplifi-
cation. A portion of the AR gene was amplified using tar-
geted PCR from the amplified whole genome DNA of
sorted C4-2 cells and WBCs. Capillary sequencing con-
firmed the known A→G point mutation in C4-2 events
with no detectable contamination from WBCs (Figure 1C).
Thus, with these FACS based methodologies, CTC isola-
tion and interrogation with specificity is feasible.
Circulating tumor cells isolation from patients with
mCRPC using FACS
To determine the applicability of these FACS-based isola-
tion techniques for interrogation of CTCs from patients
with mCRPC, 15 mL of whole blood was collected and
EpCAM+/CD45- CTCs were isolated from an initial feasi-
bility cohort of 15 patients (Table 1, Figure 2A). All pa-
tients had documented castration-resistance, and all were
progressing on their current therapy. EpCAM+/CD45-
events were isolated from 13 of 15 (87%) patients, and five
or more events were isolated from 11 of 15 (73%) subjects.
For those with isolated events, the range was 3–1700, with
a mean of 335 and a median of 237 events.LAPC-4 prostate cancer cells spiked into whole blood from healthy
flow-cytometry techniques based on expression pattern of CD45 and
ression of EpCAM and cytokeratin. B. AR-positive LAPC-4 cells and
e sorted onto slide chambers for IF and evaluated for AR staining and
r and 10 white blood cells (WBCs) were isolated by flow sorting, and
R gene was subsequently amplified and sequenced using capillary
Table 1 Clinical characteristics of the feasibility cohort
Unique ID Age (years) PSA (ng/mL) Prior therapies* Events on FACS Confirmed CTCs by IF
11001 61 1077 L, B, K, O, D, M 1700 22
11002 80 787 L, D+/−Da 294 17
11003 88 124.3 L, B 94 0
11004 76 201.3 L, T, B, N, D 0 0
11005 80 741 L, F, D, M, E vs pl 4 1
11006 58 168.1 L, B, D 0 0
11007 62 34.24 L, B, D, E 3 0
11008 63 1971 L, B, D, M + I 751 17
11009 62 68.45 L, B, D, M 60 4
11010 79 2229 L, B, D, M, Ctx 62 0
11011 71 218.9 L, B, D+/− Af, E 345 23
11012 70 1425 L 290 25
11013 72 50.15 L, B, F, K, O 431 22
11014 81 25.5 L, B, O, T 237 10
11015 80 70.8 L, B, Di, D, S 86 3
*Prior therapies: A = aflibercept, B = bicalutamide, C = cyclophosphamide, Ci = cixutumumab, D = docetaxel, Da = dasatinib, Di = diethylstilbestrol, E = enzalutamide,
F = flutamide, K = ketoconazole, L = LHRH agonist, M =mitoxantrone, N = nilutamide, O = orteronel, P = placebo, S = samarium lexidronam, T = tasquinimod.
Figure 2 Isolation of circulating tumor cells from patients with metastatic castration-resistant prostate cancer. A. Plot of gating strategy
applied on a representative patient sample capturing CD45+/ Epithelial Cell Adhesion Molecule (EpCAM)- WBCs and EpCAM+/CD45- CTCs. B.
CTCs and WBCs were sorted onto slide chambers for IF using FACS-based techniques. Cells were stained for DAPI, EpCAM, AR, and Prostate Specific
Antigen (PSA). C. The number of events for each of 51 patients who had EpCAM+/CD45- events sorted by FACS-based techniques. The mean (659) and
median (80) number of events are indicated. D. Representative CTCs evaluated by IF demonstrating AR staining. The lower panel shows variable AR
staining patterns.
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CTCs, EpCAM+/CD45- events were sorted directly onto
a chamber slide for multiplex immunofluorescence (IF)
staining for EpCAM, prostate specific antigen (PSA) and
AR followed by visualization with fluorescence micros-
copy (Figure 2B). A CTC was defined as a visualized cell
that was EpCAM+/CD45- by IF, and with an intact nucleus
(DAPI positive). Of the 13 patients with events sorted by
FACS, 10 had CTCs visualized on slide chambers ac-
cording to this definition. We were unable to visualize
CTCs from any patients with fewer than 60 sorted
EpCAM+/CD45- events. Furthermore, FACS followed by
IF staining and manual visualization lead to an approxi-
mate 90% loss of CTC events; roughly 10% of events iden-
tified by FACS were visualized on the chamber slide
(Table 1). Despite loss through the FACS-based processes,
CTC isolation from patients with progressive mCRPC was
determined to be feasible as CTCs were isolated in the
majority of patients. We next sought to utilize these
methods for CTC isolation and interrogation in an add-
itional cohort of patients. Peripheral blood was drawn
for isolation of CTCs from 42 patients (Additional file
2: Table S1). Clots formed for one sample, preventing
isolation of CTCs. Of the remaining 41 patients, CTC
events were sorted from 38 patients. In both cohorts
taken together, CTC events were identified and isolated
in 51 of 56 (91%) evaluable patients utilizing FACS-
based methodologies (median number of events 80,
mean number of events 659; Figure 2C).
Analysis of AR protein expression and localization
AR continues to play a central role in late-stage prostate
cancer, even after the development of castration-resistance,
as demonstrated by the recent FDA approval of AR
targeted therapies to treat progressive mCRPC. Our initial
effort was to therefore test the feasibility of our FACS-
based sorting methods for interrogation of the AR. We
were able to visualize AR expression, and 100% (10/10) of
patients had CTCs with greater fluorescence intensity (ex-
pression) in comparison to the AR-negative DU145 cell
line (Figure 1B). Fifty percent had AR staining intensity
higher than AR-positive LAPC-4 cells (representative pa-
tient samples, Figure 2D). Qualitatively, the majority of AR
staining within CTCs was intranuclear in subcellular
localization; however, there appeared to be variability in
AR staining intensity (expression) within and between pa-
tients (Figure 2D).
Although FACS followed by IF microscopy is feasible
and can demonstrate qualitative differences in protein
expression, these methods had several limitations, in-
cluding loss of cells when sorting onto a slide chamber,
labor-intensive protocols, and inability to obtain robust
quantitative data. We therefore shifted to utilizing the
ImageStreamX flow cytometry system for a morecomprehensive and quantitative analysis of AR protein ex-
pression and localization. ImageStreamX combines flow
cytometry with microscopy to produce multiple high reso-
lution images of each cell in real-time [25-27]. Fixing and
storing samples is also an option, which offers flexibility in
staining and analysis (Figure 3A, Additional file 3: Figure
S2). Finally, in a small pilot study of spike-in cancer cells
in another malignancy, ImageStreamX had similar cell
enumeration performance in comparison to the FDA ap-
proved CELLSEARCH system [25].
Within whole blood, CTCs are typically outnumbered
by WBCs by several logs. To reduce noise from the vastly
more abundant WBCs, and to improve visualization of
CTCs, CD45+ cells were depleted using AutoMACS
(Figure 3A). Evaluation of depleted cells confirmed that
the vast majority of events are CD45+/EpCAM- as
expected. There are however rare CD45+/EpCAM+
events within the depleted fraction; visualization of
these double-positive events suggested that these events
were the result of non-specific EpCAM staining of
debris in association with CD45+ cells and thus were
false positive events (Additional file 4: Figure S3A). To
eliminate these events we utilized the Delta Centroid
XY feature of ImageStreamX. This feature compares the
proximity of two stains, in this case EpCAM and
FxCycle Violet nuclear stain, to separate viable cells
from debris. Rare cell cluster events were noted; how-
ever these were clusters of EpCAM + CTCs along with
EpCAM- white blood cells. The intimate nature of
these cancer and non-cancer clusters confounded our
molecular characterization of these cell clusters. We
thus also used size criteria to exclude large clusters of
cells and debris (Additional file 4: Figure S3B).
We define true cells as Delta Centroid XY-gated,
area-gated events that are nucleated with an intact
membrane (Additional file 4: Figure S3C). Visualization of
ImageStreamX-captured images confirmed that 94.2% of
these events are indeed intact legitimate cells, the re-
mainder being comprised of likely cell debris (Table 2).
Furthermore, we define an ImageStreamX event as a
CTC if it is a true cell that passed CD45 depletion and
is EpCAM+. With these methods, 20 of 20 patients had
at least one CTC on 29 of 31 blood draws. For all blood
draws, there was a median of 23 (0–411) and mean of 51
(s.d. 82) CTCs (Table 2). Importantly, EpCAM+/CD45-de-
pleted cells were larger than EpCAM-/CD45-depleted cells
(Additional file 5: Figure S4), supporting their identity as
CTCs [13,29-31].
Although enumeration of CTCs is possible with Ima-
geStreamX, the rationale for use of this platform in this
study was to characterize CTCs at the molecular level.
Specifically, ImageStreamX functionality permitted fur-
ther interrogation of AR within CTCs. Importantly, we
used the LAPC-4 prostate cancer cell line as a control to
Figure 3 AR protein interrogation in CTCs from patients with metastatic castration-resistant prostate cancer using ImageStreamX. A.
Flow chart illustrating the protocol for preparing CTCs for analysis using ImageStreamX. B. Representative dot plot showing area (cell size) and AR
intensity (expression) for a single patient. Two CTCs have been selected to show corresponding images acquired using ImageStreamX technology,
which demonstrate AR-Low (top panel) or AR-high (bottom panel) expression. C. Representative histogram showing nuclear or non-nuclear AR for all
CTCs from a single patient. Nuclear AR is calculated by the similarity of AR staining and FxCycle Violet staining, and defined as Similarity Index >1. Two
CTCs have been selected to show corresponding images acquired using ImageStreamX technology.
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express the wild-type AR [32] (Additional file 6: Figure
S5). When LAPC-4 cells are treated with AR-agonist
R1881, AR protein is stabilized leading to increased ex-
pression; whereas with AR-antagonist enzalutamide, AR
expression decreases [33]. Based on these treatments, we
defined “AR-high” within CTCs as AR intensity greater
than 1 × 104 (Additional file 6: Figure S5).
Upon binding to androgen ligand, activated AR is re-
leased from heat shock proteins and translocates to the
nucleus to activate gene transcription [34]. Therefore,
nuclear localization of AR can serve as a marker suggestive
of AR activation. To quantitatively evaluate localization of
AR in CTCs using ImageStreamX, we compared the over-
laying pixel-by-pixel similarity of AR staining within the
“AR-high” cells with FxCycle Violet nuclear staining, de-
fined as the Similarity Index. As anticipated, LAPC-4 cells
with the AR-agonist R1881 causes stability and nuclearlocalization of the AR, whereas the AR-antagonist enzalu-
tamide leads to decreased AR protein levels [33]. LAPC-4
cells exposed to R1881 demonstrated a similarity index of
1 or greater, confirming nuclear localization (Additional
file 6: Figure S5), and this cutoff was therefore used to
demonstrate AR nuclear localization in patient samples.
Direct visualization of CTCs from CRPC patients with AR
staining validated this AR expression cut-off and nuclear
localization threshold in patient samples (Figure 3B,C).
We tested the reliability and reproducibility of these AR
metrics by examining intra-patient variability among bio-
logical replicates of human CTCs using ImageStreamX.
We imaged CTCs in three subjects, each of whom under-
went two blood draws within six weeks and had at least
five CTCs. Although the total number of CTCs varied be-
tween draws, the median AR expression and percentage of
CTCs with high AR staining did not vary widely between
blood draws (Additional file 7: Table S2).
Table 2 Clinical characteristics and cell-staining characteristics of patients whose CTCs were evaluated by ImageS X
Patient ID Prior therapies* PSA
(ng/mL)
EpCAM + Events CTCs (%) Mean AR
intensity# (STDev)
Median AR intensity# (Range) AR- Cs (%) Mean SI (STDev) Median SI (Range)
12077 L, B 168.4 5 4 (80) 117262 (120651) 89033 (29879–322996) 5 (1 0.67 (1.67) −0.09 (−0.43-3.55)
12076 L, B, K, A 41.16 115 114 (99) 337937 (286897) 253104 (−6509-1427349) 108 −0.12 (0.85) −0.25 (−1.79-2.31)
12079 L, B, S 32.24 104 96 (92) 25456 (36815) 11486 (1096–193627) 63 ( 0.72 (1.06) 0.57 (−0.78-4.27)
12078 L, B, K 11.12 33 27 (82) 3202 (12736) 216 (−9849-56081) 5 (1 0.97 (1.21) 0.95 (−0.98-2.06)
12080 L, B, D, C, A, E 554 0 NA NA NA NA NA NA
12081 L, D, C 275.4 36 24 (67) 33078 (58419) 4115 (−12080-240098) 16 ( −0.05 (1.51) −0.44 (−1.77-3.79)
12082 B, S 5.78 18 11 (61) 59487 (213913) 1437 (−6856-913784) 6 (3 0.39 (0.94) 0.21 (−0.62-1.64)
12083 L, B, A, E 522.3 12 11 (92) 38260 (29857) 30748 (3725–92097) 9 (7 0.3 (1.11) −0.21 (−0.98-2.39)
12084 L 164.1 24 16 (67) 78782 (214426) 795 (−5122-800180) 8 (3 0.6 (1.6) 0.17 (−1.02-3.63)
12081 L, D, C 382.6 15 5 (33) −2323 (4049) −2592 (−10466-4384) 0 NA NA
12079 L, B, S 39.3 0 NA NA NA NA NA NA
12086 B, L, K, D, A, E, Sa 1152 121 116 (96) 5674 (17971) 4256 (−13238-182505) 13 ( 0.39 (0.66) 0.6 (−0.93-1.13)
12087 L, B 20.35 35 35 (100) −11351 (21968) −7673 (−68443-33422) 4 (1 −0.46 (0.63) −0.31 (−1.33-0.12)
12086 B, L, K, D, A, E, Sa 1320 11 11 (100) 115581 (88954) 102918 (46540–360131) 11 ( −0.36 (0.44) −0.45 (−0.9-0.64)
12088 L, B, D 0.06 21 18 (86) 254074 (980505) 3184 (−1368-4502881) 4 (1 −0.2 (2.65) 0.99 (−4.17-1.38)
12028-101 L, B, D, A, E 37.23 50 48 (96) 241547 (1561372) 4910 (−3059-11054469) 12 ( 0.58 (1.51) 0.35 (−1.88-3.73)
12064-102 L, B, K, A, C 6.33 4 3 (75) 55055 (63046) 44257 (1328–130379) 2 (5 3.74 (0.35) 3.74 (3.49-3.99)
12072-103 B, L, A, D 20.59 220 215 (98) 21851 (48606) 7965 (−45736-465037) 92 ( −0.1 (0.64) −0.17 (−1.2-2.06)
12080-104 L, B, D, C, A, E 1040 3 2 (67) 81694 (72851) 108774 (−819-137127) 2 (6 2.36 (0.43) 2.36 (2.06-2.67)
14093 Ci/Et, To, Et/Te 1.83 7 6 (86) 5566 (12133) 2578 (−8042-29243) 2 (2 −0.12 (0.36) −0.12 (−0.38-0.13)
12027-105 L, B, N, K, D/Da, A, E, R 489.8 40 40 (100) 7995 (31246) 3127 (−62338-124132) 5 (1 1.32 (0.87) 1.65 (0.3-2.34)
14093 Ci/Et, To, Et/Te 1.98 23 22 (96) 500281 (2345906) 3774 (−9141-11261273) 8 (3 −0.33 (1.54) 0.06 (−3.94-1.17)
12064-102 L, B, K, A, C 6.84 411 408 (99) 11281 (21967) 7020 (−6031-267789) 115 0.74 (0.52) 0.8 (−0.75-1.82)
12072-103 B, L, A, D 25.8 30 30 (100) 12437 (37826) 4871 (−19268-203291) 8 (2 0.34 (0.68) 0.19 (−0.29-1.78)
12088 L, B, D 0.06 100 99 (99) 5505 (15912) 1670 (−13453-118622) 13 ( 0.01 (0.61) −0.17 (−0.89-1.3)
14092 L, B, K, N, A, R 498.7 13 11 (85) 51770 (97952) 689 (−60783-230484) 5 (3 1.86 (0.82) 2.03 (0.48-2.6)
12028-101 L, B, D, A, E 46.31 29 27 (93) 23411 (69628) 4050 (−5317-359215) 7 (2 0.92 (1.22) 0.37 (−0.62-2.85)











































Table 2 Clinical characteristics and cell-staining characteristics of patients whose CTCs were evaluated by ImageStreamX (Continued)
14090 L, B, N, S, A 6.81 10 8 (80) 41168 (90507) −4692 (−83596-201844) 4 (40) 2.38 (0.52) 2.38 (1.76-3.02)
14089 L, B 5.06 11 9 (82) 192342 (687361) −2246 (−149355-2254943) 3 (27) 2.33 (1.29) 1.71 (1.47-3.82)
14089 L, B 5.87 8 2 (25) 1953000 (5025861) 218121 (−25632-14383254) 6 (75) 1.02 (1.71) 1.53 (−2.35-2.49)
Thirty-one blood draws from 20 patients were evaluated by ImageStreamX technology, of which 29 blood draws from 20 patients had CTCs identified. SI = similarity index.
*Prior therapies: A = abiraterone, B = bicalutamide, C = cabazitaxel, Ci = cisplatin, D = docetaxel, Da = dasatinib, E = enzalutamide, Et = etoposide, K = ketoconazole, L = LHRH agonist, N = nilutamide, R = radium223,
S = sipuleucel-T, Sa = samarium, Te = temozolemide, To = topotecan.
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AR staining of patient CTC samples demonstrated inter-
subject variability in expression and localization of AR
(Table 2, Figure 4A,B). For the entire population the me-
dian AR intensity was (38260) with a very wide range of
(−11,351 - 1,953,000). Furthermore, as exemplified in
Figure 3B, within a patient the AR expression was vari-
able; populations of CTCs expressing high levels of AR
were visualized within the same sample with low AR ex-
pressing CTCs. Nuclear localization of AR showed simi-
lar population differences within a patient (example
Figure 3C). This suggests that a patient may have het-
erogeneous CRPC biology with respect to AR.
Association of prior therapy and proliferation status with
AR characterization
To further test whether AR expression and nuclear
localization may be clinically relevant, we sought to
examine AR biology as it relates to prior CRPC therapy.
This was a clinically diverse cohort of mCRPC patients
(Table 2), with variable exposure to potent AR targeted
therapies, including the androgen synthesis inhibitor
abiraterone acetate. Within our cohort of 20 patients, 10
had previously received abiraterone, and 6 had received
the AR antagonist enzalutamide, all 6 of whom had also
received abiraterone. We sought to test the hypothesis
that patients whose disease had progressed despiteFigure 4 Heterogeneous AR expression intensity and
localization in patients with advanced prostate cancer. Plots
showing the (A) median AR intensity or (B) median similarity index
of CTCs from 29 blood draws from 20 patients with advanced
prostate cancer.abiraterone would have altered AR expression within
CTCs. For example, we would hypothesize that after fail-
ure of this AR targeted therapy, CTCs may have lower
AR expression and less nuclear (active) AR if a non-AR
mediated pathway of clinical resistance is evident. Inter-
estingly, there was a significant increase in AR expres-
sion within CTCs from patients with prior abiraterone
treatment and progression (N = 10) compared to abira-
terone naïve patients (N = 10) (median AR staining in-
tensity 7020 [Interquartile range 4153–37503] vs. 2124
[216–4115], p < 0.05). There was no significant change
in cellular localization pattern within CTCs from pa-
tients with prior abiraterone exposure (Figure 5). These
data suggest compensation by cancer cells after exposure
to abiraterone by increasing AR expression. There were
no patients who received enzalutamide but not abirater-
one, and AR expression level in those who progressed
on both abiraterone and enzalutamide was similar to
that of patients who progressed on abiraterone but were
naïve to enzalutamide (median 4910 [IQR 4153–66833]
vs 7020 [4153–37503], p = 0.97).
To determine if AR remains a driver of proliferation in
this heterogeneous cohort of patients with mCRPC, we
also examined co-expression of AR and Ki-67, a well-
established marker of proliferation (Additional file 8:
Figure S6A-C) [35]. Interestingly, AR-high cells expressed
higher levels of Ki-67 than AR-low cells (Figure 6A,B).
Similarly, AR positive cells with nuclear AR localization
expressed higher levels of Ki-67 than cells with cyto-
plasmic AR localization (Figure 6A,C). These data de-
pict an association between AR expression and nuclear
localization and cancer cell proliferation in patients with
advanced prostate cancer, even in the setting of castration-Figure 5 Association between prior exposure to abiraterone
and increased AR expression. Box-and-whisker plots showing (A)
median AR intensity or (B) median similarity index of CTCs from
patients with prior exposure to abiraterone versus no prior exposure
to abiraterone (abi = abiraterone) (* p-value <0.05).
Figure 6 Correlation of AR expression or nuclear localization with
expression of the proliferation marker Ki-67. A. Representative
images of two cells acquired with ImageStreamX that were multiplex
stained for Ki-67, AR, and FxCycle Violet. Images represent cells with
low AR expression, non-nuclear AR, and low Ki-67 staining (top panel)
or high AR expression, nuclear AR, and high Ki-67 staining (bottom
panel). B. Box-and-whisker plot showing the Ki-67 expression of AR-low
(AR intensity <103), AR-intermediate (AR intensity 103 – 104), and
AR-high (AR intensity >104) CTCs from all samples that had Ki-67
staining and cells in all three AR expression groups (n = 16 patients).
C. Box-and-whisker plot showing the Ki-67 expression of CTCs with low
similarity index (SI <0), intermediate similarity index (SI 0–1), or high
similarity index (SI >1) from all samples that had Ki-67 staining and cells
in all three similarity index groups (n = 10 patients) (* p-value <0.05,
** p-value <0.01, *** p-value <0.001).
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therapies.
Discussion
A major unmet need in personalization of prostate cancer
care is the identification and validation of therapeutic bio-
markers. One major limitation in our ability to develop
biomarkers for mCRPC therapies is the difficulty in
obtaining patient tumor specimens that are reflective of
their current disease biology. CTC interrogation offers a
potential source of such biomaterial; however, evaluation
of CTCs is logistically difficult, and to date, there are no
established methods for the study of CTCs at the molecu-
lar level. The principal goal of this study was to develop a
novel, logistically feasible and robust method for interro-
gating CTCs from patients with progressive CRPC. Given
the central importance of AR biology in prostate cancertherapeutics, our focus was on utilizing these techniques
to study AR within CTCs.
We demonstrate the feasibility of two different flow
cytometry-based techniques for the evaluation of CTCs
from blood of men with progressive mCRPC. Our ap-
proach is streamlined and uses equipment that is widely
available. Furthermore, fixation of cells for ImageS-
treamX allowed for short-and-long term storage of cells,
facilitating greater experimental flexibility, and templates
used during sample acquisition and data analysis were
able to be standardized. The specificity of the cells iso-
lated and evaluated was confirmed subsequent to FACS
CTC isolation. Direct visualization and staining of these
events confirmed that these were cells that expressed
EpCAM, PSA and AR, but not CD45, and contained a
nucleus.
The focus of the majority of CTC evaluation to date
has been enumeration. While this is informative and
prognostic [36], CTC isolation with molecular profiling
of advanced disease has the potential to advance the
personalization of CRPC therapy. Clinical trials are be-
ginning to tailor therapy to specific molecular subtypes,
and the analysis of CTCs will be a vital tool in identify-
ing which therapies are most appropriate for each
patient.
To that end, our goal was to show feasibility of isola-
tion and molecular profiling of CTCs from patients with
mCRPC. Given the pivotal role of AR, we focused our
analysis on the expression and subcellular localization of
AR. We found that AR expression and localization is
heterogeneous between patients, and even within a pa-
tient. The finding that patients have CTCs with pleio-
tropic AR expression and localization is novel and may
suggest variable or incomplete efficacy of AR-targeted
therapies for such patients. Whether specific clones are
selected under the therapeutic pressure of specific agents
is an obvious avenue of further investigation.
With our quantitative analysis of AR protein expres-
sion using the ImageStreamX platform, our results could
have implications for future clinical research with em-
bedded CTC biomarker interrogation. We initially hy-
pothesized that after failure of abiraterone, patients
would have less active AR (demonstrated by less AR ex-
pression or nuclear localization) supporting clinical pro-
gression through a non-AR directed mechanism. In fact,
our data support that patients with prior exposure to
abiraterone have higher AR protein expression and sta-
tistically unchanged AR nuclear localization compared
to patients who were not exposed to abiraterone. This
parallels previously reported xenograft models showing
increased AR expression in prostate cancer after abira-
terone [37,38]. Our data suggest that combining abira-
terone with an AR antagonist such as enzalutamide may
be effective in those patients, and especially in patients
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tional phase III clinical trial of enzalutamide and abirater-
one in combination is underway testing this hypothesis
(NCT01949337). We also show, for the first time, that
CTCs with nuclear AR have more Ki-67 staining com-
pared to CTCs with cytoplasmic AR, implying that cells
with nuclear AR are more proliferative. These results con-
firm that AR remains important in mCRPC patients des-
pite clinical attempts to disrupt AR signaling. Thus, use of
AR expression and localization in CTCs to guide manage-
ment decisions warrants further investigation.
The parameters used to identify cells of interest are of
concern when identifying rare events. We chose to focus
on EpCAM+ cells due to the wealth of experience sup-
porting these selection criteria. It may well be, however,
that there are additional markers which could allow
identification/isolation of CTCs [39-41], which we are
not collecting/isolating with our current techniques.
One major benefit of the ImageStreamX multiplex protein
interrogation approach is its flexibility; as our understand-
ing of CTC biology becomes more refined, one could eas-
ily replace EpCAM-specific antibodies with other targeted
markers. Of note, we did identify EpCAM-/AR + cells with
ImageStreamX. These were noted to be smaller than the
EpCAM+ cells as a whole, leading to the presumption that
the majority of these events are white blood cells that es-
caped negative selection. However, it is possible that they
are EpCAM-low CTCs, and further evaluation of this
population in particular is needed.
The relatively small sample size of this feasibility study is
a limitation. A larger prospective study in a homogeneous
patient population is needed to validate quantitative AR
protein characterization within CTCs as a therapeutic bio-
marker. Fixed cells analyzed by ImageStreamX are not
suitable for further interrogation of DNA or RNA expres-
sion. This is a limitation of our protein-based analysis plat-
form. Of note, our initial FACS-based approach does allow
for DNA interrogation with specificity, although this was
not the focus of this current study.
There are many considerations when developing novel
techniques for isolating and interrogating CTCs as potential
biomarkers [13]. One primary question that remains largely
unanswered is to what extent CTCs are representative of
the metastatic disease. The fact that CTC enumeration is
prognostic for CRPC suggests a link between CTC and
metastatic disease burden, but to what extent the CTCs are
in fact part of the metastatic process is not clear. One small
study of prostate cancer patients showed a lymph node me-
tastasis was phylogenetically more closely related to the
CTCs and to one particular focus of the primary prostate
tumor than other prostate tumor foci [42]. The field of
CTC research is still in its relative infancy and new molecu-
lar techniques will enable further characterization of the re-
lationship biologically between CTC and metastasis.Other groups have performed highly elegant experiments
examining CTC genomics and expression for other diseases
[43,42]. In CRPC, reports of CTC molecular interrogation
are limited, but have included proteins associated with
epithelial to mesenchymal transition and genomic
changes such as loss of PTEN or TMPRSS-ERG translo-
cations [39,41]. IHC methods have also been described
to ascertain AR expression in CTCs [44]. Furthermore, in
a recent study, single-cell immunofluorescence was used
to suggest whether CTCs had active or suppressed AR sig-
naling, determined by PSA and PSMA, respectively, in un-
treated and CRPC patients [12]. Evaluation of AR isoform
expression may have clinical value. A recent study showed
that expression of the AR variant AR-v7 in CTCs may be
associated with primary resistance to abiraterone and
enzalutamide [45].
ImageStreamX analysis could easily be adapted to
evaluate for expression of AR-v7 using anti-AR-v7 anti-
bodies [8]. Of note, the AR antibody used in the present
study is raised against a relatively N-terminal peptide,
which is expected to bind to common truncated splice
variants, including AR-V7. Mutation in the AR has also
been demonstrated in mCRPC [46,47]. These mutation
or ligand independent splice variations have been shown
to lead to enhanced activation of the AR. Although our
protein-centric methods do not allow for the detection of
these specific genetic or mRNA events, ImageStreamX is
able to quantify nuclear localization of the AR, which is a
surrogate for active nuclear hormone receptor. Other
groups have also published reports suggesting AR subcel-
lular localization in CTCs has clinical value. In their study,
Darshan et. al found that cytoplasmic AR status in CTCs
correlated with favorable clinical response to taxane
chemotherapy [48]. Our methods complement and expand
on these studies utilizing quantitative methodologies to in-
terrogate AR protein expression in CTCs.
In summary, our focus on AR protein analysis in
CTCs has demonstrated that interrogation of AR ex-
pression and subcellular localization may have clinical
relevance. Alterations in these metrics are associated
with progression on abiraterone and increased expres-
sion of a marker of cellular proliferation. Given the
continued focus on AR as a therapeutic target in
mCRPC, quantitative analysis of AR expression and nu-
clear localization has the potential to serve as a predict-
ive therapeutic biomarker. Further validation of our
techniques, in the context of prospective clinical trials
is warranted. As our ability to personalize prostate can-
cer management improves, streamlined CTC isolation
and molecular profiling will become an integral piece
in the management of advanced prostate cancer. Al-
though we focus on AR expression for the purpose of
this study involving patients with mCRPC, our quanti-
tative multiplexing methods are adaptable for other
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broadly applicable to other metastatic malignancies.
Conclusions
We provide molecular characterization of the AR signaling
pathway in circulating prostate cancer cells. We have dem-
onstrated feasibility of AR characterization, showing vari-
ation in AR expression and localization. AR expression and
nuclear localization in CTCs may be a dynamic therapeutic
biomarker worthy of future validation in a more homoge-
neous patient population in the context of an AR-targeted
therapy. As methods for isolation and characterization of
CTCs improve, CTCs may become established as a clinical
tool to guide the management of advanced prostate cancer.
Additional files
Additional file 1: Figure S1. Single stain compensation controls. Dot
plots showing single stain compensation controls of VCAP or CWR22RV1
cells that were stained for EpCAM, AR, Ki-67, or FxCycle Violet.
Additional file 2: Table S1. Numbers of CTCs isolated by FACS-sorting.
Numbers of CTCs isolated for 42 patients, in addition to the feasibility
cohort shown in Table 1.
Additional file 3: Figure S2. Fixing cells does not alter EpCAM
intensity. Flow cytometry dot plots showing control cells (left), or unfixed
(middle) or fixed (right) LAPC-4 prostate cancer cells stained for EpCAM.
Additional file 4: Figure S3. Use of ImageStreamX to confirm CTCs as
EpCAM+, CD45-depleted cells. A. Patient cells were CD45-depleted using
a biotinylated anti-CD45 antibody. CD45 positive cells were stained with
Streptavidin-Alexa488 and cells were acquired on ImageStreamX. EpCAM
and CD45 were mutually exclusive, and double positive events were cell
debris or cell clusters. B. Gating using Delta Centroid XY feature eliminates
debris. Representative images from a patient sample demonstrating that
Delta Centroid XY high events are false positive and Delta Centroid XY low
events are true CTCs. Events were gated on FxCycle + EpCAM+Delta
Centroid XY+. C. Patient CTCs are EpCAM+ FxCycle + and have an intact
membrane. Representative images from two separate patients acquired
through ImageStreamX showing events considered to represent viable CTCs
(top panel) and those considered to represent cellular debris (bottom panel).
Additional file 5: Figure S4. EpCAM + blood cells are larger than
EpCAM- blood cells. Area of CD45-depleted, EpCAM + or EpCAM- cells.
Area is calculated using ImageStreamX technology (*** p-value <0.001).
Additional file 6: Figure S5. AR positive cells are defined by AR intensity
of 104 or greater. LAPC-4 prostate cancer cells were treated with the AR
agonist R1881 (1nM, top panel) or the AR antagonist enzalutamide (10 μM,
bottom panel). Cells were stained for intracellular AR and analyzed using
ImageStreamX. LAPC-4 cells lose AR expression in the presence of the AR
inhibitor enzalutamide, indicating the threshold for AR-high cells is AR
intensity level 104.
Additional file 7: Table S2. CTCs from repeat blood draws analyzed by
ImageStreamX. Table comparing intra-patient variability of the median AR
intensity and similarity index for three patients whose blood was drawn
at two different time points within six weeks.
Additional file 8: Figure S6. Ki-67 intensity is higher in proliferating
cells. Dot plots showing Ki-67 intensity of CWR22RV1 cells treated with
(A) 1 μM or (B) 8 μM of mitomycin, which inhibits proliferation. C. Boxplot
depicting Ki-67 intensity in each population (** p-value <0.01).
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